We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Kelly
Lavender-Smith
K.Lavender-Smith@mmu.ac.uk
Tiago
Pecanha
T.Pecanha@mmu.ac.uk
Michelle
Barraclough
michelle.barraclough@manchester.ac.uk
Tiago
Pecanha
T.Pecanha@mmu.ac.uk
Systemic connective tissue disordersSymptoms and signs involving cognition, perception, emotional state and behaviour
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease marked by fluctuating symptoms and multiple system involvement. SLE patients often experience neuropsychiatric disorders, such as anxiety/depression, headache, and cognitive dysfunction. Among them, cognitive dysfunction is one of the most prevalent (affecting 38% of all patients) and debilitating symptoms in SLE, with a profound socioeconomic impact. The precise causes of cognitive dysfunction in SLE are uncertain but may arise from structural/functional changes in the brain, which need to be better investigated using comprehensive neuroimaging methods. Additionally, there are still limited treatment options for cognitive dysfunction in SLE. In recent years, physical activity has been widely explored in the clinical management of symptom burden in SLE, showing positive effects in the control of the disease and improvement of quality life. However, it is currently unknown if having a physically active lifestyle associates with better cognitive function on SLE, warranting further investigation. The present project is an observational study that will collect data on cognitive function, brain structure and function and physical activity in individuals with SLE. Specifically, the project intends to explore underlying brain mechanisms associated with cognitive dysfunction in SLE; and the associations between physical activity/sedentary behaviour and cognitive function in SLE. Twenty four individuals with SLE and 12 healthy controls will attend The Institute of Sport at Manchester Metropolitan University, where they will undergo a comprehensive assessment of cognitive function, brain structural and functional magnetic resonance imaging (fMRI) scans, and will perform physical testing and assess their physical activity levels using accelerometry. Participants with SLE will be grouped by the presence/absence of cognitive dysfunction and be compared with healthy controls.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
Participants with Lupus: • Exclusion criteria, individuals: o Who have had a previous stroke or heart attack. o With signs, symptoms, or diagnosis of cardiovascular diseases (coronary heart disease, peripheral arterial disease, valve disease, heart failure). o With respiratory (severe asthma, COPD, cystic fibrosis) or severe renal (eGFR< 30 ml/min/1.73 m2) diseases, uncontrolled diabetes, or current cancer. o With any contradiction of the MRI facility Safety Checklist. Participants with metal implants or devices, such as pacemakers, defibrillators, cochlear implants, certain types of joint replacements, or aneurysm clips, will be exuded due to potential risks associated with exposure with the magnetic field. Female participants who are, or could be, pregnant will also be excluded. o With any physical disability or musculoskeletal impairment that prevents the performance of the studies procedures. o With a difficulty understanding English. o With severe claustrophobia. o With severe visual deficits. Healthy controls: • Exclusion criteria, individuals: o Who have had a previous stroke or heart attack. o With signs, symptoms, or diagnosis of cardiovascular diseases (coronary heart disease, peripheral arterial disease, valve disease, heart failure). o With respiratory (severe asthma, COPD, cystic fibrosis) or severe renal (eGFR< 30 ml/min/1.73 m2) diseases, uncontrolled diabetes, or current cancer. o With any contradiction of the MRI facility Safety Checklist. Participants with metal implants or devices, such as pacemakers, defibrillators, cochlear implants, certain types of joint replacements, or aneurysm clips, will be exuded due to potential risks associated with exposure with the magnetic field. Female participants who are, or could be, pregnant will also be excluded. o With any physical disability or musculoskeletal impairment that prevents the performance of the studies procedures. o With major health problems including any disease that may affect cognitive performance (e.g. stroke, alcoholism, dementia, epilepsy). o With a difficulty understanding English. o With severe claustrophobia. o With severe visual deficits.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Kelly
Lavender-Smith
K.Lavender-Smith@mmu.ac.uk
Tiago
Pecanha
T.Pecanha@mmu.ac.uk
Tiago
Pecanha
T.Pecanha@mmu.ac.uk
Michelle
Barraclough
michelle.barraclough@manchester.ac.uk
The study is sponsored by Manchester Metropolitan University and funded by Lupus UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 58041
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
